SCHEMBL6152646

SCHEMBL6152646

O=CNc1nc(CC(=O)Cl)cs1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 3/20 0.41
MAPT P10636 5/20 0.40
GAA P10253 5/20 0.40
PDE5A O76074 3/20 0.40
PDE1A P54750 1/20 0.40
PDE1B Q01064 1/20 0.40
PDE1C Q14123 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
KDM4E B2RXH2 2/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213000 0.85 GABRA5 (0.53) SMN1; SMN2KMT2AALDH1A1MAPTGAA
Hydrochloric Acid SCHEMBL6152648 0.84 GABRA5 (0.51) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL11143253 0.84 KMT2A (0.40) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL11143259 0.84 CSNK2A1 (0.46) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL10134063 0.81 ALDH1A1 (0.58) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL9050304 0.80 SMN1; SMN2 (0.56) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL676084 0.78 SMN1; SMN2 (0.64) SMN1; SMN2KMT2AALDH1A1MAPTGAA
SCHEMBL2448139 0.77 SCD (0.39) SMN1; SMN2KMT2AALDH1A1MAPTPOLB
Hydrochloric Acid SCHEMBL9329409 0.76 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AALDH1A1MAPTNPC1
SCHEMBL9686219 0.76 KMT2A (0.53) SMN1; SMN2KMT2AALDH1A1GAAPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016024284-A2 A PROCESS FOR THE PREPARATION OF MIRABEGRON AND ITS INTERMEDIATES WANBURY LTD. (IN) 2016-02-18 WO disclosed
EP-1278754-B1 CEPHALOSPORIN INTERMEDIATES SANDOZ AG (CH) 2005-01-26 EP disclosed
US-6787649-B2 Cephalosporin intermediates SANDOZ GMBH (AT) 2004-09-07 US disclosed
US-20030153748-A1 Cephalosporin intermediates SANDOZ GMBH (FORMERLY BIOCHEMIE GMBH) (AU) 2003-08-14 US disclosed
EP-1278754-A1 CEPHALOSPORIN INTERMEDIATES BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 2003-01-29 EP disclosed
WO-2001083491-A1 CEPHALOSPORIN INTERMEDIATES BIOCHEMIE GESELLSCHAFT M B H (AT) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153748-A1 Cephalosporin intermediates MRPL21, MGAM, BLVRB SMN1; SMN2 4631/4885KMT2A 3987/4885ALDH1A1 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.